Biomedical Engineering Reference
In-Depth Information
References
1. Yamamoto T, Takahara A (2009) Recent updates of N-type calcium channel blockers with
therapeutic potential for neuropathic pain and stroke. Curr Top Med Chem 9:377-395
2. McGivern JG (2006) Targeting N-type and T-type calcium channels for the treatment of pain.
Drug Discov Today 11:245-253
3. Hirning LD, Fox AP, McCleskey EW et al (1988) Dominant role of N-type Ca
2+
channels in
evoked release of norepinephrine from sympathetic neurons. Science 239:57-61
4. Saegusa H, Kurihara T, Zong S et al (2001) Suppression of inflammatory and neuropathic pain
symptoms in mice lacking the N-type Ca
2+
channel. EMBO J 20:2349-2356
5. Saegusa H, Matsuda Y, Tanabe T (2002) Effects of ablation of N- and R-type Ca
2+
channels on
pain transmission. Neurosci Res 43:1-7
6. Snutch TP (2005) Targeting chronic and neuropathic pain: the N-type calcium channel comes
of age. NeuroRx 2:662-670
7. Wermeling DP, Berger JR (2006) Ziconotide infusion for severe chronic pain: case series of
patients with neuropathic pain. Pharmacotherapy 26:395-402
8. Feng ZP, Hamid J, Doering C et al (2001) Residue Gly1326 of the N-type calcium channel
a
1B
subunit controls reversibility of
o
-conotoxin GVIA and MVIIA block. J Biol Chem
276:15728-15735
9. Ellinor PT, Zhang JF, Horne WA et al (1994) Structural determinants of the blockade of N-type
calcium channels by a peptide neurotoxin. Nature 372:272-275
10. Liang H, Elmslie KS (2002) Rapid and reversible block of N-type calcium channels (CaV 2.2)
by
-conotoxin GVIA in the absence of divalent cations. J Neurosci 22:8884-8890
11. Yarotskyy V, Elmslie KS (2009)
o
-Conotoxin GVIA alters gating charge movement of N-type
(CaV2.2) calcium channels. J Neurophysiol 101:332-340
12. Buraei Z, Anghelescu M, Elmslie KS (2005) Slowed N-type calcium channel (CaV2.2)
deactivation by the cyclin-dependent kinase inhibitor roscovitine. Biophys J 89:1681-1691
13. Buraei Z, Elmslie KS (2008) The separation of antagonist from agonist effects of trisubstituted
purines on CaV2.2 (N-type) channels. J Neurochem 105:1450-1461
14. Buraei Z, Schofield G, Elmslie KS (2007) Roscovitine differentially affects CaV2 and Kv
channels by binding to the open state. Neuropharmacology 52:883-894
15. DeStefino NR, Pilato AA, Dittrich M et al (2010) (R)-Roscovitine prolongs the mean open time
of unitary N-type calcium channel currents. Neuroscience 167:838-849
16. Yarotskyy V, Elmslie KS (2007) Roscovitine a cyclin-dependent kinase inhibitor, affects
several gating mechanisms to inhibit cardiac L-type (Ca(V)1.2) calcium channels. Br
J Pharmacol 152:386-395
17. Carafoli E, Santella L, Branca D et al (2001) Generation, control, and processing of cellular
calcium signals. Crit Rev Biochem Mol Biol 36:107-260
18. Snutch TP, Larry RS (2009) Voltage-gated calcium channels, Encyclopedia of neuroscience.
Oxford Academic Press, Oxford, pp 427-441
19. Nowycky MC, Fox AP, Tsien RW (1985) Three types of neuronal calcium channel with
different calcium agonist sensitivity. Nature 316:440-443
20. Tokuhara N, Namiki K, Uesugi M et al (2010) N-type calcium channel in the pathogenesis of
experimental autoimmune encephalomyelitis. J Biol Chem 285(43):33294-33306
21. Petrashevskaya NN, Ishii M, D'Souza K et al (2011) Presynaptic stimulus-release and
postsynaptic compensatory changes in mice lacking the N-type calcium channel
o
a
1B
-subunit.
Auton Neurosci 160(1-2):9-15
22. Yaksh TL (2006) Calcium channels as therapeutic targets in neuropathic pain. J Pain
7:S13-S30
23. Vanegas H, Schaible H (2000) Effects of antagonists to high-threshold calcium channels upon
spinal mechanisms of pain, hyperalgesia and allodynia. Pain 85:9-18
